10 December 2020>: Clinical Research
Repeat Administration of Bone Marrow-Derived Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis
Tomasz Siwek 12ABDEFG* , Katarzyna Jezierska-Woźniak 3ABDEF , Stanisław Maksymowicz 4BCDEF , Monika Barczewska 56BD , Mariusz Sowa 56B , Wanda Badowska 7B , Wojciech Maksymowicz 56ADGDOI: 10.12659/MSM.927484
Med Sci Monit 2020; 26:e927484
Table 1 Demographic and statistical data.
Age | Sex | Clinical form of ALS | Progression rate | Monthly decrease in ALSFRS-R scores before treatment | Monthly decrease in ALSFRS-R scores after treatment | Change in progression rate | |
---|---|---|---|---|---|---|---|
Patient 1 | 41 | F | Limb-onset | Slow | 0.3 | 1.0 | Increased |
Patient 2 | 46 | M | Limb-onset | Slow | 0.6 | 0.7 | No change |
Patient 3 | 53 | F | Bulbar | Fast | 2.9 | 0.3 | Decreased |
Patient 4 | 43 | M | Limb-onset | Slow | 0.7 | 0.8 | No change |
Patient 5 | 53 | F | Bulbar | Slow | 0.3 | 1.3 | Increased |
Patient 6 | 72 | M | Limb-onset | Slow | 0.7 | 0.7 | No change |
Patient 7 | 54 | M | Bulbar | Slow | 0.3 | 0.3 | No change |
Patient 8 | 47 | M | Limb-onset | Fast | 1.2 | 0.2 | Decreased |